19 June 2021 - 08:00-12:00

1: Doctor I am so tired it worries me more than my shake
Daniel van Wamelen, London, United Kingdom

2: I have dystonia but why cant I sleep?
Lisa Klingelhöfer, Dresden, Germany

3: Can genes tell me about my pain and precision treatment in Parkinson’s?
K. Ray Chaudhuri, London, United Kingdom

1:Immunological basis of MS-fatigue and therapeutic implications
Thomas Berger, Vienna, Austria

2: Functional correlates and diagnostics of fatigue in RRMS/SPMS
Iris Penner, Düsseldorf, Germany

3: MS-Fatigue from a somnologist's perspective
Stine Knudsen-Heier, Oslo, Norway

1: Transition from paediatric to adult care: Treatments for rare diseases the adult neurologist needs to know about.
Ulrike Schara-Schmidt, Essen, Germany

2: Rare neuromuscular disorders: from precise diagnosis to personalized treatment
Teresinha Evangelista, Paris, France

3: Rare and complex epilepsy syndromes: from precise diagnosis to personalized treatment
Eugen Trinka, Salzburg, Austria

1: Neuroinflammation in epilepsy: not only autoimmune encephalitis
Mar Carreno, Barcelona, Spain

2: Genetics in epilepsy: not only abnormal channels
Sameer Zuberi, Glasgow, United Kingdom

3: mTOR pathway in epilepsy: not only Tuberous Sclerosis Complex
Renzo Guerrini, Florence, Italy

08:00 - 09:30 Focused Workshop 4: 

1: Reduction of the safety factor in myasthenic syndromes
Hakan Cetin, Vienna, Austria

2: Fetal and adult AChRs in congenital myasthenic syndromes
David Beeson, Oxford, United Kingdom

3: Fetal and adult AChRs in autoimmune myasthenic syndromes
Angela Vincent, Oxford, United Kingdom

1: Multimodal neuromonitoring to guide precision medicine in neurocritical care
TBA

2: Artificial Intelligence in neurocritical care
Nils Schweingruber, Hamburg, Germany

3: Ethico- legal aspects of artificial intelligence in neurocritical care
Berna Arda, Ankara, Turkey

1: Infections as triggers of autoimmune encephalitis and related disorders
Sergio Muñiz Castrillo, Bron Cedex, France

2: Infections as triggers of other central nervous system autoimmune disorders
David Garcia Azorin, Valladolid, Spain

3: Infections as triggers of Guillain-Barré syndrome
Johann Sellner, Mistelbach, Austria

1: Language symptoms and testing, in aging, aphasia and cognitive decline
Isabel Pavão Martins, Lisbon, Portugal

2: Language disorders in neurodegenerative diseases
Chiara Cerami, Pavia, Italy

3: Language Connectomics
Michel Thiebaut de Schotten, Bordeaux, France

1: Hereditary spastic paraplegia
Caterina Mariotti, Milan, Italy

2: Stiff person syndrome and related disorders
Maria Stamelou, Athens, Greece

3: Stiff legs: rare causes and mimics
Kailash Bhatia, London, United Kingdom

TBA

1: Sleep Apnea and Cerebrovascular Disease- 2021 update
James Stevens, Indiana, USA

2: REM Sleep Behaviour Disorder (RBD): future implications for neurodegenerative disease
Claudia Trenkwalder, Kassel, Germany

3: Narcolepsy: An immune-mediated hypothalamic disease
Claudio Bassetti, Bern, Switzerland

4: Restless Legs Syndrome: Recent results from pathophysiological and imaging studies.
Birgit Högl, Innsbruck, Austria

5: Is Paradoxical (REM) sleep a motor state?
Pierre-Hervé Luppi, Lyon, France

1: Imaging for Parkinson's Disease and Parkinsonism
Irena Rektorova, Brno, Czech Republic

2: Has Genetics Changed Management of Parkinson's Disease and other Synucleinopathies  
Alessio Di Fonzo, Milan, Italy

3: Laboratory biomarkers for diagnosis of PD, other synucleinopathies and atypical parkinsonian syndromes – is there evidence?
Per Svenningsson, Stockholm, Sweden

4: Neuropathologic Signature of synuclein dissemination in Parkinson’s disease
Tiago Outeiro, Göttingen, Germany 

1: Epileptogenesis after intial insult
Asla Pitkänen, Kuopio, Finland

2: Stroke, Seizures, and Epilepsy – Precision from the clinical perspective
Tim von Oertzen, Linz, Austria

3: Infections as etiology of epilepsy, treatment and prognosis
Matthias Koepp, London, United Kingdom

4: Posttraumatic epilepsy -current treatment
Marte Helene Bjørk, Bergen, Norway

1: Are we able to prevent or minimize the symptoms in leukodystrophies?
Ludger Schöls, Tübingen, Germany

2: How early diagnosis helps to prevent the cardiological manifestations in neuromuscular disorders
Marianne de Visser, Amsterdam, The Netherlands

3: Personalized preventive approaches for stroke prevention in neurogenetic disorders
Anita Arsovska, Skopje, Macedonia

1: Advancing precision care in advanced MS – the EAN Guideline
Alessandra Solari, Milan, Italy

2: Personalised Care of Late Stage Parkinsonism – the CLaSP study
Stefan Lorenzl, Salzburg, Austria

3: Personalised palliative care improves quality of life for neurological patients
David Oliver, Canterburry, United Kingdom

1: Targeted therapy for glioblastoma
Emilie Le Rhun, Zurich, Switzerland

2: Targeted therapy for rare brain tumors
Roberta Rudà, Turin, Italy

3: Targeted therapy for brain metastasis
Matthias Preusser, Vienna, Austria

4: Targeted therapies for brain tumors in children
Sabine Müller, San Francisco, United States of America

1: Effects of aging and Alzheimer’s disease on spatial navigation
Vladislava Segen, Magdeburg, Germany

2: Spatial navigation deficits as cognitive markers for preclinical Alzheimer's disease
Jan Laczo, Prague, Czech Republic

3: Neurological disorders of spatial orientation and navigation
Thomas Brandt, Munich, Germany